Drug to treat diabetic macular edema meets midstage study goals

The AP (2/19) reports that on Feb. 18, Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG announced that “their VEGF Trap-Eye drug” now under development for treatment of diabetic macular edema “met key vision improvement goals in a midstage study.” In the 24-week study, researchers “compared VEGF Trap-Eye with laser therapy.” Reuters (2/18, Kuber) points out that diabetic macular edema is a common cause of vision loss in some patients with diabetes.

For more information on vision and eye care issues visit youreyesite.com.

Follow Dr. Glazier’s tweets @EyeInfo.  Help provide free eyecare for people in need just by joining the EyeHealth Information Network on Facebook.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: